Sulphate iron
PreclinicalSmall molecule
Sulphate iron is one of 13 small molecule programs targeting Celiac Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Celiac Disease
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Advil
KKenvue Brands
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
VIOKACE
DDigestive Care, Inc.
Approved
DONQ52
RochePhase 2
Xifaxan
SSalix
Preclinical
Hepatitis B Vaccine
SanofiPreclinical
FB102
FForte Biosciences, Inc.
Phase 2
ZED1227
DDr. Falk Pharma GmbH
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Celiac Disease1 trial
Sucrosomial Iron in Patients With Celiac Disease and IDA
Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·N/A·NCT02916654·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulphate iron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details